Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534313 | 0.90 | CYP1A2 (0.58) | IDO1CYP1A2CYP2D6CYP2C19AGXT | |
| SCHEMBL12392041 | 0.84 | IDO1 (0.50) | IDO1CYP1A2CYP2D6CYP2C19AGXT | |
| SCHEMBL22862637 | 0.84 | IDO1 (0.50) | IDO1CYP1A2CYP2D6CYP2C19AGXT | |
| SCHEMBL13877377 | 0.84 | IDO1 (0.50) | IDO1CYP1A2CYP2D6CYP2C19AGXT | |
| Hydrochloric Acid SCHEMBL4239938 | 0.83 | IDO1 (0.52) | IDO1CYP1A2CYP2D6CYP2C19AGXT | |
| SCHEMBL11307378 | 0.81 | IDO1 (0.45) | IDO1CYP1A2CYP2D6CYP2C19AGXT | |
| SCHEMBL5469848 | 0.81 | CYP1A2 (0.47) | IDO1CYP1A2CYP2D6CYP2C19AGXT | |
| SCHEMBL5460913 | 0.81 | CYP1A2 (0.47) | IDO1CYP1A2CYP2D6CYP2C19AGXT | |
| SCHEMBL134443 | 0.80 | IDO1 (0.46) | IDO1AGXTLMNATP53ACACB | |
| SCHEMBL764954 | 0.79 | IDO1 (0.65) | IDO1ACACBL3MBTL1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | HIF1AN, EGLN2, EGLN3 | IDO1 587/4885CYP1A2 506/4885CYP2D6 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.